Prognostic Impact of PPP2R5C Gene Expression in Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
Maha El TaweelRafaat Abdelfattah

Abstract

Protein Phosphatase 2A (PP2A) is a crucial regulator of the cellular signalling pathways, proliferation, cell cycle checkpoints and apoptosis. The PPP2R5C gene encodes PP2A regulatory B56γ subunit. Malignant transformation may occur, if mRNA of PPP2R5C is functionally deregulated, structurally altered, decreased or overexpressed. Therefore, the purpose of the study was to examine PPP2R5C mRNA expression, evaluate its association with the different clinical and haematological parameters and determine its prognostic impact in Egyptian adult acute myeloid leukaemia patients with normal cytogenetics (CN-AML). Peripheral blood samples of 50 de novo CN-AML patients and 20 age- and gender-matched healthy controls were examined for PPP2R5C expression by Quantitative Real Time-Polymerase Chain Reaction. The expression levels of PPP2R5C mRNA were significantly higher in the CN-AML samples than in the control samples (P ≤ 0.001). There was a statistical significant difference between the low and high expression levels of PPP2R5C with regard to age (P = 0.005, r = - 0.447, P = 0.001). The patients with an unfavourable response to induction chemotherapy had significant higher PPP2R5C expression levels than those with a favourable response (...Continue Reading

References

Jan 22, 2005·Current Opinion in Genetics & Development·Veerle JanssensChristine Van Hoof
Jul 26, 2005·Experimental Hematology·Susann FältAnders Wennborg
May 24, 2006·The Journal of Biological Chemistry·Stephen S LinThomas M Roberts
Dec 19, 2006·Cell·Yanhui XuYigong Shi
Jul 1, 2008·Biochimica Et Biophysica Acta·Pieter J A EichhornRené Bernards
May 10, 2011·Journal of Hematology & Oncology·Haitao ZhengYangqiu Li
Mar 5, 2013·Cancer Letters·Parthasarathy SeshacharyuluSurinder K Batra
May 4, 2013·The Lancet Oncology·Danilo Perrotti, Paolo Neviani
Sep 21, 2013·Journal of Molecular and Cellular Cardiology·Jordi HeijmanDobromir Dobrev
Sep 3, 2014·Journal of Cell Science·Peng XuSang Hyun Lee
Jan 8, 2015·Frontiers in Oncology·Dorien HaesenVeerle Janssens
Oct 29, 2015·The FEBS Journal·Jaya SangodkarGoutham Narla
Feb 26, 2016·Critical Reviews in Biochemistry and Molecular Biology·Nathan Wlodarchak, Yongna Xing
Apr 20, 2016·Frontiers in Oncology·Elena ArriazuMaría D Odero
Jul 9, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellNdiya Ogba
Jul 22, 2018·Biochimica Et Biophysica Acta. Molecular Cell Research·Peter P Ruvolo
Mar 31, 2019·Clinical Lymphoma, Myeloma & Leukemia·Mosaad M El GammalJerald P Radich

❮ Previous
Next ❯

Citations

Jan 16, 2021·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Daoliang SongXin Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.